AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Company Description
First Wave BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of targeted and non-systemic therapies for the treatment of patients with gastrointestinal diseases.
Its product candidates include latiglutenase, a targeted oral biotherapeutic for celiac disease designed to breakdown gluten into non-immunogenic peptides; biologic adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients; capeserod, a selective 5-HT4 receptor partial agonist to treat gastroparesis; and niclosamide, an oral small molecule with anti-inflammatory properties for patients with inflammatory bowel diseases, such as ulcerative colitis and Crohn's disease.
It is also developing CypCel, a disease management tool for monitoring the intestinal health of recovering celiac disease patients.
The company was formerly known as AzurRx BioPharma, Inc. and changed its name to First Wave BioPharma, Inc. in September 2021.
First Wave BioPharma, Inc. was incorporated in 2014 and is headquartered in Boca Raton, Florida.
Country | United States |
IPO Date | Oct 11, 2016 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 9 |
CEO | James R. Sapirstein M.B.A., R.Ph. |
Contact Details
Address: 777 Yamato Road Boca Raton, Florida United States | |
Website | https://www.firstwavebio.com |
Stock Details
Ticker Symbol | n/a |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | n/a |
CUSIP Number | n/a |
ISIN Number | US33749P4081 |
Employer ID | - |
SIC Code | n/a |
Key Executives
Name | Position |
---|---|
James R. Sapirstein M.B.A., R.Ph. | Chief Executive Officer & Chairman |
Sarah Romano CPA | Chief Financial Officer |
Amy Chandler-Skerkis | Vice President of Regulatory Affairs, QA & Compliance |
Jennifer A. Sealey-Voyksner Ph.D. | Senior Vice President for Research & Development |
Martin Krusin M.B.A. | Senior Vice President of Corporate Development |